Vnitr Lek 2016, 62(12):976-984

The benefit of magnetic resonance for diagnosing cardiomyopathy and myocarditis

Michal Fikrle1,2, Petr Kuchynka2, Martin Mašek3, Jana Podzimková2, Jan Kuchař2, Aleš Linhart2, Tomáš Paleček2,*
1 Kardiologické oddělení Nemocnice Jihlava
2 II. interní klinika - klinika kardiologie a angiologie 1. LF UK a VFN v Praze
3 Radiodiagnostická klinika 1. LF UK a VFN v Praze

Magnetic resonance is becoming an increasingly used examination in cardiology, since it greatly improves the accuracy of diagnosing of many heart diseases. At present magnetic resonance is the gold standard in assessing the volumes of the heart chambers and the systolic function of both ventricles. The possibility of detecting tissue characteristics to refine the diagnostics of different types of myocardial pathology is of essential importance. The authors summarize in the article the present knowledge about the use of magnetic resonance of the heart in the field of myocardial disease, i.e. cardiomyopathy and myocarditis. In the first of this article, a general overview of cardiac magnetic resonance examination has been given, followed by detailed description of its usefulness in dilated cardiomyopathy and myocarditis, in hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy. The second part of the review summarizes the benefits of cardiac magnetic resonance examination in cardiac amyloidosis and other less common cardiomyopathies.

Keywords: fibrosis; cardiomyopathy; magnetic resonance; myocarditis; late contrast agent saturation

Received: June 19, 2016; Accepted: August 1, 2016; Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fikrle M, Kuchynka P, Mašek M, Podzimková J, Kuchař J, Linhart A, Paleček T. The benefit of magnetic resonance for diagnosing cardiomyopathy and myocarditis. Vnitr Lek. 2016;62(12):976-984.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arbustini E, Weidemann F, Hall JL. Left Ventricular Noncompaction A Distinct Cardiomyopathy or a Trait Shared by Different Cardiac Diseases? J Am Coll Cardiol 2014; 64(17): 1840-1850. Go to original source... Go to PubMed...
    2. Jenni R, Oechslin E, Schneider J et al. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy. Heart 2001; 86(6): 666-671. Go to original source... Go to PubMed...
    3. Petersen SE, Selvanayagam JB, Wiesmann F et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol 2005; 46(1): 101-105. Go to original source... Go to PubMed...
    4. Jacquier A, Thuny F, Jop B et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur Heart J 2010; 31(9): 1098-1104. Go to original source... Go to PubMed...
    5. Captur G, Muthurangu V, Cook C et al. Quantification of left ventricular trabeculae using fractal analysis. J Cardiovasc Magn Reson 2013; 15: 36. Dostupné z DOI: <http://dx.doi.org/10.1186/1532-429X-15-36>. Go to original source... Go to PubMed...
    6. Dawson DK, McLernon DJ, Raj VJ et al. Cardiovascular Magnetic Resonance Determinants of Left Ventricular Noncompaction. Am J Cardiol 2014; 114(3): 456-462. Go to original source... Go to PubMed...
    7. Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart 2011; 97(1): 75-84. Go to original source... Go to PubMed...
    8. Fikrle M, Palecek T, Masek M et al. The diagnostic performance of cardiac magnetic resonance in detection of myocardial involvement in AL amyloidosis. Clin Physiol Funct Imaging 2016; 36(3): 218-224. Go to original source... Go to PubMed...
    9. Karamitsos TD, Piechnik SK, Banypersad SM et al. Noncontrast T1 Mapping for the Diagnosis of Cardiac Amyloidosis. JACC Cardiovasc Imaging 2013; 6(4): 488-497. Go to original source... Go to PubMed...
    10. Dubrey SW, Falk RH. Diagnosis and Management of Cardiac Sarcoidosis. Prog Cardiovasc Dis 2010; 52(4): 336-346. Go to original source... Go to PubMed...
    11. Smedema JP, Snoep G, van Kroonenburgh MP et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005; 45(10): 1683-1690. Go to original source... Go to PubMed...
    12. Salemi VM, Rochitte CE, Shiozaki AA et al. Late gadolinium enhancement magnetic resonance imaging in the diagnosis and prognosis of endomyocardial fibrosis patients. Circ Cardiovasc Imaging 2011; 4(3): 304-311. Go to original source... Go to PubMed...
    13. Moon JC, Sachdev B, Elkington AG et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003; 24(23): 2151-2155. Go to original source... Go to PubMed...
    14. Imbriaco M, Spinelli L, Cuocolo A. MRI characterization of myocardial tissue in patients with Fabry's disease. Am J Roentgenol 2007; 188(3): 850-853. Go to original source... Go to PubMed...
    15. Pica S, Sado DM, Maestrini V et al. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2014; 16: 99. Dostupné z DOI: <http://dx.doi.org/10.1186/s12968-014-0099-4>. Go to original source... Go to PubMed...
    16. Boucek D, Jirikowic K, Taylor M. Natural history of Danon disease. Genet Med 2011; 13(6): 563-568. Go to original source... Go to PubMed...
    17. Majer F, Pelak O, Kalina T et al. Mosaic tissue distribution of the tandem duplication of LAMP2 exons 4 and 5 demonstrates the limits of Danon disease cellular and molecular diagnostics. J Inherit Metab Dis 2014; 37(1): 117-124. Go to original source... Go to PubMed...
    18. Verhaert D, Richards K, Rafael-Fortney JA et al. Cardiac Involvement in Patients with Muscular Dystrophies, Magnetic Resonance Imaging Phenotype and Genotypic Considerations. Circ Cardiovasc Imaging 2011; 4(1): 67-76. Go to original source... Go to PubMed...
    19. Anderson LJ, Holden S, Davis B et al. Cardiovascular T2-star (T2) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22(23): 2171-2179. Go to original source... Go to PubMed...
    20. Kirk P, Roughton M, Porter JB et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120(20): 1961-1968. Go to original source... Go to PubMed...
    21. Abdel-Aty H, Cocker M, Friedrich MG. Myocardial edema is a feature of Tako-Tsubo cardiomyopathy and is related to the severity of systolic dysfunction: insights from T2-weighted cardiovascular magnetic resonance. Int J Cardiol 2009; 132(2): 291-293. Go to original source... Go to PubMed...
    22. Deetjen AG, Conradi G, Mollmann S et al. Value of gadolinium-enhanced magnetic resonance imaging in patients with Tako-Tsubo-like left ventricular dysfunction. J Cardiovasc Magn Reson 2006; 8(2): 367-372. Go to original source... Go to PubMed...
    23. Sliwa K, Hilfiker-Kleiner D, Petrie MC et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Failure 2010; 12(8): 767-778. Go to original source... Go to PubMed...
    24. Mouquet F, Lions C, de Groote P et al. Characterisation of peripartum cardiomyopathy by cardiac magnetic resonance imaging. Eur Radiol 2008; 18(12): 2765-2769. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.